A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
At a glance
- Drugs ABT 122 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 25 Jul 2017 Results of pooled analysis from three phase I studies including this study published in the Clinical Pharmacokinetics
- 13 Jun 2015 Results presented (in pooled analysis of 3 phase I trials) at the 16th Annual Congress of the European League Against Rheumatism.
- 03 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.